What triggered the latest move in Doximity (DOCS)
Doximity (DOCS) recently issued financial results with revenue guidance that fell short of investor expectations, along with commentary on higher AI related expenses and margin pressures. This was followed by a securities law investigation from Pomerantz LLP.
The combination of a softer forward outlook and concerns around the cost of AI investments has sharpened the market’s focus on how the company balances growth initiatives with profitability, and what that might mean for the stock’s risk profile.
See our latest analysis for Doximity.
Doximity’s US$19.94 share price has bounced in the last week, with a 7 day share price return of 5.11% after a sharp 30 day share price decline of 16.95%. The year to date share price return of 53.94% decline alongside a 1 year total shareholder return of 60.92% decline points to fading momentum despite recent AI product integrations, leadership changes, updated guidance and the securities law investigation.
If you are looking beyond a single healthcare AI platform, this is a good moment to see how other listed healthcare AI stocks are trading through the 34 healthcare AI stocks.
With revenue growing, earnings under pressure and the share price down sharply over the past year, the key question now is whether Doximity’s valuation reflects these cross currents or if the stock is already pricing in future growth.
Most Popular Narrative: 47.2% Undervalued
At a last close of $19.94 versus a narrative fair value of $37.77, the most followed Doximity storyline frames the stock as materially discounted, with that gap tied directly to a detailed set of revenue, margin and valuation assumptions.
The expanded adoption of AI-powered workflow tools (Scribe, Doximity GPT, and Pathway AI) is expected to further entrench Doximity as a core clinician productivity suite, driving frequency of platform use, deeper customer retention, and ultimately higher average revenue per user (ARPU) over time, supporting long-term revenue and margin expansion.
Want to see what kind of revenue runway, margin profile and future earnings multiple are baked into that valuation gap? The core of this narrative leans on measured growth expectations, steady profitability and a richer multiple than the broader healthcare services group, all tied together under a single fair value number.
Result: Fair Value of $37.77 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, heavy spending on mostly free AI tools and Doximity’s reliance on pharmaceutical marketing budgets could quickly challenge this undervaluation story if monetization or funding weakens.
Find out about the key risks to this Doximity narrative.
Next Steps
With sentiment clearly split between opportunity and risk, this is a good time to review the numbers yourself, decide how you feel about Doximity’s setup, and then follow up by checking the 2 key rewards
Looking for more investment ideas?
If Doximity has sharpened your focus on quality and risk, do not stop here. Broaden your watchlist now so you do not miss the next standout opportunity.
- Spot potential mispricing early by checking stocks that look attractively valued on cash flows and balance sheets through the 49 high quality undervalued stocks.
- Lock in income-focused opportunities by scanning for companies offering robust payouts in the 10 dividend fortresses.
- Prioritise resilience by reviewing companies that combine financial strength with lower risk profiles using the 67 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com